ArticleOncotarget2018
Coronary artery disease risk in young women with polycystic ovary syndrome.
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 4 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Polycystic ovary syndrome with stroke, hypertension, and cardiovascular diseases: a systematic review and meta-analysis.BMC women's health · 2025Pooled it
- 2023 International Evidence-Based Polycystic Ovary Syndrome Guideline Update: Insights From a Systematic Review and Meta-Analysis on Elevated Clinical Cardiovascular Disease in Polycystic Ovary Syndrome.Journal of the American Heart Association · 2024Pooled it
- Risk of hypertension in women with polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression.Reproductive biology and endocrinology : RB&E · 2020Pooled it
- Risk of Cardiovascular and Cerebrovascular Events in Polycystic Ovarian Syndrome Women: A Meta-Analysis of Cohort Studies.Frontiers in cardiovascular medicine · 2020Pooled it
- Article
- Emulating a target trial of surgical removal of uterine fibroids on atherosclerotic cardiovascular disease.Fertility and sterility · 2026Article
- Risk of cardiovascular and cerebrovascular events in polycystic ovarian syndrome women: An updated meta-analysis of cohort studies.Turkish journal of obstetrics and gynecology · 2025Article
- Atherogenic ApoB-dyslipidemia, atherosclerotic cardiovascular disease, cardiac dysfunction and remodeling in high-risk young women with and without polycystic ovary syndrome: A pilot study.Frontiers in endocrinology · 2025Article
- The Cardiometabolic Risk in Women with Polycystic Ovarian Syndrome (PCOS): From Pathophysiology to Diagnosis and Treatment.Medicina (Kaunas, Lithuania) · 2024Review
- 2024 Guidelines of the Taiwan Society of Cardiology on the Primary Prevention of Atherosclerotic Cardiovascular Disease --- Part I.Acta Cardiologica Sinica · 2024Article
- The IL-12 family of heterodimeric cytokines in polycystic ovarian syndrome: biological role in induction, regulation, and treatment.Immunologic research · 2024Review
- Polycystic Ovary Syndrome, Insulin Resistance, and Cardiovascular Disease.Current cardiology reports · 2024Review
- Polycystic Ovary Syndrome Physiologic Pathways Implicated Through Clustering of Genetic Loci.The Journal of clinical endocrinology and metabolism · 2024Article
- Article
- Metabolic hormones are integral regulators of female reproductive health and function.Bioscience reports · 2024Review
- Interplay between lipid profile and anthropometric measures as indicators of cardiometabolic risk in women with polycystic ovary syndrome.Frontiers in endocrinology · 2024Article
- Article
- Polycystic Ovarian Syndrome: a Risk Factor for Cardiovascular Disease.Current atherosclerosis reports · 2023Review
- Symptom Presentation among Women with Suspected Ischemia and No Obstructive Coronary Artery Disease (INOCA).Journal of clinical medicine · 2023Article
- Cardiovascular disease risk in women with hyperandrogenism, oligomenorrhea/menstrual irregularity or polycystic ovaries (components of polycystic ovary syndrome): a systematic review and meta-analysis.European heart journal open · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Women with polycystic ovary syndrome are characterized by obesity, menstruation irregularity, hirsutism and infertility, and prevalent with cardiometabolic comorbidities, but population-based studies on the risk of developing coronary artery disease are limited. From claims data of the Taiwan National Health Insurance, we identified 8048 women with polycystic ovary syndrome aged 15-49 years newly diagnosed in 1998-2013, and 32192 women without the syndrome and CAD as controls, frequency matched by age and diagnosis date. By the end of 2013, after a mean follow-up period of 5.9 years, the overall incidence of coronary artery disease was 63% higher in women with polycystic ovary syndrome than in controls (2.25 vs. 1.38 per 1000 person-years). The adjusted hazard ratio [aHR] of coronary artery disease was 1.44 (95% confidence interval (CI) = 1.14-1.81) for women with polycystic ovary syndrome, compared with controls. Hazards of coronary artery disease were significant during follow-up periods of 3-4 years (aHR = 1.52, 95% CI = 1.00-2.30) and of 5-9 years (aHR = 1.58, 95% CI = 1.07-2.32). The incidence of coronary artery disease increased further in those with cardiometabolic comorbidities. Among women with polycystic ovary syndrome, those with comorbid diabetes had an incidence of 35.2 per 1000 person-years, 20-fold greater than those without cardiometabolic comorbidities. In conclusion, women with polycystic ovary syndrome are at an elevated risk of coronary artery disease. Preventive interventions should be provided to them, particularly for those with the comorbidity of metabolism symptom.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.